Orphazyme upgrades after careful spending year
Several reporting parameters have been adjusted upward by biotech firm Orphazyme, which has fared better than feared in 2021.
by marketwire, translated by daniel pedersen
Orphazyme tightened its belt in 2021, resulting in lower-than-expected costs for the year. Now, the biotech company is upgrading its 2021 financial forecast a few months prior to the report's full release, a press release announced on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme makes changes to board of directors
For subscribers
